Compare Charles River Laboratories Intl. Inc (CRL) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs US Bancorp — how do they compare? Charles River Laboratories Intl. Inc trades at $299.03 (market cap $14.23B), while US Bancorp trades at $56.63 (market cap $88.86B). The key difference: US Bancorp is far larger — about 6.2× Charles River Laboratories Intl. Inc's market cap, and US Bancorp pays a 3.79% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and US Bancorp for 97 Days on average.
| CRL | USB | |
|---|---|---|
Market Cap | $14.23B | $88.86B |
Volume | 1,176,885 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $310.77 | $65.42 |
52-Week Low | $149.93 | $45.28 |
Typical Hold Time | 33 Days | 97 Days |
Enterprise Value | $17.06B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
U.S. Bancorp (USB) trades at $56.17, down 1.95% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock offers a $2.16 annual dividend yield with recent 3.8% increase. Analyst consensus is bullish with $69.94 price target despite near-term technical weakness.
USB presents a value opportunity with attractive P/E of 11.38 and strong profitability metrics, though investors face interest rate sensitivity and regulatory uncertainty risks. The bank's solid earnings track record and dividend growth support long-term investment case despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
